A review of avelumab in locally advanced and metastatic bladder cancer

Research output: Contribution to journalReview article

Abstract

Urothelial carcinoma remains a devastating disease with a poor prognosis. Though immune therapy with Bacillus Calmette-Guérin (BCG) has been used for localized bladder cancer for years, only immune-checkpoint blockade with antiprogrammed cell-death 1 (anti-PD-1) and antiprogrammed cell-death ligand 1 (anti-PD-L1) inhibitors have demonstrated improvement in survival of patients with metastatic disease. Anti-PD-L1 antibody, avelumab, was recently given United States Food and Drug Administration (FDA) accelerated approval for the treatment of recurrent/metastatic urothelial carcinoma after failure of first-line chemotherapy, marking the fifth immune checkpoint inhibitor to be given FDA approval for the treatment of metastatic urothelial cancer. The following manuscript will review avelumab, its pharmacology, and the clinical experience that has led to its approval, as well as future plans for clinical development of avelumab for the treatment or urothelial cancer.

Original languageEnglish (US)
Pages (from-to)1756287218823485
JournalTherapeutic Advances in Urology
Volume11
DOIs
StatePublished - Feb 8 2019

Fingerprint

Urinary Bladder Neoplasms
United States Food and Drug Administration
Cell Death
Carcinoma
Drug Approval
Manuscripts
Clinical Pharmacology
Therapeutics
Bacillus
Neoplasms
Ligands
Drug Therapy
Survival
avelumab
Antibodies

PubMed: MeSH publication types

  • Journal Article
  • Review

Cite this

A review of avelumab in locally advanced and metastatic bladder cancer. / Rao, Arpit; Patel, Manish R.

In: Therapeutic Advances in Urology, Vol. 11, 08.02.2019, p. 1756287218823485.

Research output: Contribution to journalReview article

@article{54fcb81340514baeae528a06b00f72b1,
title = "A review of avelumab in locally advanced and metastatic bladder cancer",
abstract = "Urothelial carcinoma remains a devastating disease with a poor prognosis. Though immune therapy with Bacillus Calmette-Gu{\'e}rin (BCG) has been used for localized bladder cancer for years, only immune-checkpoint blockade with antiprogrammed cell-death 1 (anti-PD-1) and antiprogrammed cell-death ligand 1 (anti-PD-L1) inhibitors have demonstrated improvement in survival of patients with metastatic disease. Anti-PD-L1 antibody, avelumab, was recently given United States Food and Drug Administration (FDA) accelerated approval for the treatment of recurrent/metastatic urothelial carcinoma after failure of first-line chemotherapy, marking the fifth immune checkpoint inhibitor to be given FDA approval for the treatment of metastatic urothelial cancer. The following manuscript will review avelumab, its pharmacology, and the clinical experience that has led to its approval, as well as future plans for clinical development of avelumab for the treatment or urothelial cancer.",
author = "Arpit Rao and Patel, {Manish R}",
year = "2019",
month = "2",
day = "8",
doi = "10.1177/1756287218823485",
language = "English (US)",
volume = "11",
pages = "1756287218823485",
journal = "Therapeutic Advances in Urology",
issn = "1756-2872",
publisher = "SAGE Publications Inc.",

}

TY - JOUR

T1 - A review of avelumab in locally advanced and metastatic bladder cancer

AU - Rao, Arpit

AU - Patel, Manish R

PY - 2019/2/8

Y1 - 2019/2/8

N2 - Urothelial carcinoma remains a devastating disease with a poor prognosis. Though immune therapy with Bacillus Calmette-Guérin (BCG) has been used for localized bladder cancer for years, only immune-checkpoint blockade with antiprogrammed cell-death 1 (anti-PD-1) and antiprogrammed cell-death ligand 1 (anti-PD-L1) inhibitors have demonstrated improvement in survival of patients with metastatic disease. Anti-PD-L1 antibody, avelumab, was recently given United States Food and Drug Administration (FDA) accelerated approval for the treatment of recurrent/metastatic urothelial carcinoma after failure of first-line chemotherapy, marking the fifth immune checkpoint inhibitor to be given FDA approval for the treatment of metastatic urothelial cancer. The following manuscript will review avelumab, its pharmacology, and the clinical experience that has led to its approval, as well as future plans for clinical development of avelumab for the treatment or urothelial cancer.

AB - Urothelial carcinoma remains a devastating disease with a poor prognosis. Though immune therapy with Bacillus Calmette-Guérin (BCG) has been used for localized bladder cancer for years, only immune-checkpoint blockade with antiprogrammed cell-death 1 (anti-PD-1) and antiprogrammed cell-death ligand 1 (anti-PD-L1) inhibitors have demonstrated improvement in survival of patients with metastatic disease. Anti-PD-L1 antibody, avelumab, was recently given United States Food and Drug Administration (FDA) accelerated approval for the treatment of recurrent/metastatic urothelial carcinoma after failure of first-line chemotherapy, marking the fifth immune checkpoint inhibitor to be given FDA approval for the treatment of metastatic urothelial cancer. The following manuscript will review avelumab, its pharmacology, and the clinical experience that has led to its approval, as well as future plans for clinical development of avelumab for the treatment or urothelial cancer.

U2 - 10.1177/1756287218823485

DO - 10.1177/1756287218823485

M3 - Review article

VL - 11

SP - 1756287218823485

JO - Therapeutic Advances in Urology

JF - Therapeutic Advances in Urology

SN - 1756-2872

ER -